Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr Battiwalla on the Utility of Emerging Therapies for Aggressive FL Management

November 19th 2024

Minoo Battiwalla, MD, MS, discusses how emerging therapies contribute to the management of aggressive variants of follicular lymphoma.

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

November 15th 2024

The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with relapsed or refractory acute leukemia and a KMT2A translocation.

Dr Awan on Treatment Considerations With Pirtobrutinib in Hematologic Malignancies

November 15th 2024

Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.

Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML

November 15th 2024

Venetoclax plus 10-day decitabine was safe and produced responses in AML and high-risk MDS.

FDA Approves Nilotinib Tablets Without Mealtime Restrictions for CML

November 14th 2024

The FDA has approved nilotinib tablets without mealtime restrictions for select patients with chronic myeloid leukemia.

Data for Nivolumab Plus AVD Could Help Harmonize Treatment of Older and Younger Advanced-Stage Hodgkin Lymphoma

November 14th 2024

Alex F. Herrera, MD, discusses long-term data from nivolumab plus AVD in advanced-stage Hodgkin lymphoma.

Real-World Experience With CAR T Varies From Trials in DLBCL

November 13th 2024

When evaluating real-world experience, differences in race/ethnicity and among elderly patients with DLBCL appeared different from those seen in clinical trials, highlighting the need for consideration in these patient populations.

Revumenib Meets CR/CRh End Point in NPM1+ R/R AML

November 12th 2024

Revumenib met the CR/CRh primary end point of the phase 2 AUGMENT-101 trial in NPM1-mutated acute myeloid leukemia.

Early Serum IL-2 Levels Are Associated With CAR T-Cell Expansion Post–CAR T-Cell Therapy

November 11th 2024

Early cytokine induction after CAR T-cell therapy infusion predicts CAR expansion in patients with leukemia or lymphoma treated with axi-cel or brexu-cel.

The OncFive: Top Oncology Articles for the Week of 11/3

November 9th 2024

Obe-cel wins FDA approval in relapsed/refractory B-cell ALL, FDA approval is sought for sunvozertinib in EGFR exon 20–positive NSCLC, and more.

FDA Approves Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

November 8th 2024

The FDA has approved obecabtagene autoleucel for relapsed/ refractory B-cell precursor acute lymphoblastic leukemia.

NICE Advocates Reimbursement for Avapritinib in Aggressive Systemic Mastocytosis, Other Hematologic Malignancies

November 6th 2024

NICE issued a final guidance recommending reimbursement of avapritinib monotherapy in adult patients with ASM, SM-AHN, or mast cell leukemia.

OncLive’s October Roundup of Key FDA Approvals in Oncology

November 5th 2024

Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.

The OncFive: Top Oncology Articles for the Week of 10/27

November 2nd 2024

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.

Revisit Every OncLive On Air Episode From October 2024

November 1st 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in October 2024.

Dr Foss on the FDA Approval of Denileukin Diftitox for CTCL

October 31st 2024

Francine Foss, MD, discusses the FDA approval of denileukin diftitox for the treatment of patients with CTCL.

Precision Medicine Unfolds in Oncology, Bearing Substantial Implications for the Future

October 30th 2024

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the inner workings of oncology: https://rb.gy/bvumdn.

Dr Fisher on the Integration of Bispecific Antibodies and CAR T-cell Therapy into CRS Treatment

October 29th 2024

David C. Fisher, MD, discusses treatment with bispecific antibodies and CAR T-cell therapy, respectively, for patients with cytokine release syndrome.

The Future of Hematologic Cancer Care Shifts Toward Personalized and Chemotherapy-Free Regimens

October 29th 2024

Daniel DeAngelo MD, PhD, discusses the evolution of management strategies and treatment goals across several hematologic malignancies.

FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Ph+ Chronic-Phase Chronic Myeloid Leukemia

October 29th 2024

The FDA has granted accelerated approval to asciminib for newly diagnosed, Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.